Clinical Trial Update: An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD) [Phase 2]

View source ↗

Summary

An extension study of ABBV-8E12 in early Alzheimer’s disease (Phase 2) was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ABBV-8E12 (ABBV-8E12)

Snippet

Sponsor: AbbVie | Conditions: Alzheimer's Disease | Phase 2 | Status: TERMINATED | Results posted: 2022-09-22